← ANALYST RATINGS · TIPRANKS
Geron (GERN): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $4.33, the highest $6.00, the lowest $3.00. The average is +270.4% from the last price of $1.17.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.00 → $1.50+50.0% | Hold | +28.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.00 → $1.50+50.0% | Hold | +28.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Hold | +28.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.00 | Hold | −14.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +28.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Hold | +28.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | — | Hold | — | Reiterated | 21.09.26on TipRanks Sep 22 06:10 | −1.6%next day +0.8% · 5 days −2.8% | ↗ |
| Unknown Analyst | Wedbush | $6.00 | Buy | +412.8% | Reiterated | 06.08.26on TipRanks 10:13 | −3.5%next day −6.3% · 5 days −3.4% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $3.00 | Buy | +156.4% | Assigned | 05.08.26on TipRanks Aug 6 05:55 | +21.8%next day −3.5% · 5 days −4.0% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $4.00 | Buy | +241.9% | Reiterated | 05.08.26on TipRanks 14:35 | +21.8%next day −3.5% · 5 days −4.0% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $1.00 | Sell | −14.5% | Reiterated | 25.02.26on TipRanks Feb 26 07:35 | −12.6%next day −3.5% · 5 days −13.4% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | — | Buy | — | Reiterated | 03.11.25on TipRanks 17:20 | −3.0%next day −5.6% · 5 days +7.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Geron
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $4.33 at a price of $1.23 (+252.3%); now: $4.33 at $1.17 (+270.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.01 (from $-0.02 to $0.00). Last quarter: $-0.02.
Sales
Next quarter’s sales estimate — $61M (from $57M to $63M). Last quarter: $57M.
Best top-analyst consensus in the sector · Healthcare
About Geron
- CEO: Harout Semerjian
- Employees: 258
- 919 East Hillsdale Boulevard, Foster City, CA, 94404, US
- www.geron.com
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Data from the stock’s TipRanks forecast page, read 137 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗